322 related articles for article (PubMed ID: 1845172)
41. The use of 4-aminobiphenyl hemoglobin adducts and aromatic DNA adducts in lymphocytes of smokers as biomarkers of exposure.
Dallinga JW; Pachen DM; Wijnhoven SW; Breedijk A; van 't Veer L; Wigbout G; van Zandwijk N; Maas LM; van Agen E; Kleinjans JC; van Schooten FJ
Cancer Epidemiol Biomarkers Prev; 1998 Jul; 7(7):571-7. PubMed ID: 9681524
[TBL] [Abstract][Full Text] [Related]
42. Detection of DNA adducts in human oral tissue: correlation of adduct levels with tobacco smoking and differential enhancement of adducts using the butanol extraction and nuclease P1 versions of 32P postlabeling.
Jones NJ; McGregor AD; Waters R
Cancer Res; 1993 Apr; 53(7):1522-8. PubMed ID: 8453617
[TBL] [Abstract][Full Text] [Related]
43. 4-Aminobiphenyl hemoglobin adducts in fetuses exposed to the tobacco smoke carcinogen in utero.
Coghlin J; Gann PH; Hammond SK; Skipper PL; Taghizadeh K; Paul M; Tannenbaum SR
J Natl Cancer Inst; 1991 Feb; 83(4):274-80. PubMed ID: 1994056
[TBL] [Abstract][Full Text] [Related]
44. Biochemical (postlabelling) methods for analysis of carcinogen-DNA adducts.
Randerath K; Randerath E; Agrawal HP; Reddy MV
IARC Sci Publ; 1984; (59):217-31. PubMed ID: 6443609
[TBL] [Abstract][Full Text] [Related]
45. 1,N2-propanodeoxyguanosine adducts: potential new biomarkers of smoking-induced DNA damage in human oral tissue.
Nath RG; Ocando JE; Guttenplan JB; Chung FL
Cancer Res; 1998 Feb; 58(4):581-4. PubMed ID: 9485001
[TBL] [Abstract][Full Text] [Related]
46. Immunochemical quantitation of DNA adducts derived from the human bladder carcinogen 4-aminobiphenyl.
Roberts DW; Benson RW; Groopman JD; Flammang TJ; Nagle WA; Moss AJ; Kadlubar FF
Cancer Res; 1988 Nov; 48(22):6336-42. PubMed ID: 3180051
[TBL] [Abstract][Full Text] [Related]
47. Analysis of 4-ABP-DNA adducts and p53 alterations in urinary bladder carcinoma.
Romano G; Garagnani L; Boninsegna A; Ferrari P; Flamini G; De Gaetani C; Sgambato A; Giovanni F; Curigliano G; Ferretti G; Cittadini A; Trentini G
Anticancer Res; 1999; 19(5C):4571-6. PubMed ID: 10650812
[TBL] [Abstract][Full Text] [Related]
48. Combined micropreparative techniques with synchronous fluorescence spectroscopy or 32P-postlabelling assay for carcinogen-DNA adduct determination.
Shields PG; Kato S; Bowman ED; Petruzzelli S; Cooper DP; Povey AC; Weston A
IARC Sci Publ; 1993; (124):243-54. PubMed ID: 8225491
[TBL] [Abstract][Full Text] [Related]
49. High-performance liquid chromatographic analysis of 32P-postlabeled DNA-aromatic carcinogen adducts.
Levy GN; Weber WW
Anal Biochem; 1988 Nov; 174(2):381-92. PubMed ID: 3239743
[TBL] [Abstract][Full Text] [Related]
50. 32P-postlabeling analysis of adducts generated by peroxidase-mediated binding of N-hydroxy-4-acetylaminobiphenyl to DNA.
Hatcher JF; Swaminathan S
Carcinogenesis; 1995 Sep; 16(9):2149-57. PubMed ID: 7554068
[TBL] [Abstract][Full Text] [Related]
51. 32P-postlabeling assay for carcinogen-DNA adducts and other dna modifications.
Randerath K; Randerath E
J UOEH; 1989 Mar; 11 Suppl():368-86. PubMed ID: 2664950
[TBL] [Abstract][Full Text] [Related]
52. Carcinogen-DNA adducts in bladder biopsies and urothelial cells: a risk assessment exercise.
Talaska G; Schamer M; Casetta G; Tizzani A; Vineis P
Cancer Lett; 1994 Aug; 84(1):93-7. PubMed ID: 8076366
[TBL] [Abstract][Full Text] [Related]
53. Alkylaniline-hemoglobin adducts and risk of non-smoking-related bladder cancer.
Gan J; Skipper PL; Gago-Dominguez M; Arakawa K; Ross RK; Yu MC; Tannenbaum SR
J Natl Cancer Inst; 2004 Oct; 96(19):1425-31. PubMed ID: 15467031
[TBL] [Abstract][Full Text] [Related]
54. Aromatic amine DNA adduct formation in chronically-exposed mice: considerations for human comparison.
Poirier MC; Beland FA
Mutat Res; 1997 May; 376(1-2):177-84. PubMed ID: 9202754
[TBL] [Abstract][Full Text] [Related]
55. Epidemiological models of carcinogenesis: the example of bladder cancer.
Vineis P
Cancer Epidemiol Biomarkers Prev; 1992; 1(2):149-53. PubMed ID: 1306098
[TBL] [Abstract][Full Text] [Related]
56. Carcinogen hemoglobin adducts, urinary mutagenicity, and metabolic phenotype in active and passive cigarette smokers.
Wu JM
J Natl Cancer Inst; 1991 Jul; 83(13):963. PubMed ID: 2067040
[No Abstract] [Full Text] [Related]
57. DNA adduct levels in congenic rapid and slow acetylator mouse strains following chronic administration of 4-aminobiphenyl.
Flammang TJ; Couch LH; Levy GN; Weber WW; Wise CK
Carcinogenesis; 1992 Oct; 13(10):1887-91. PubMed ID: 1423849
[TBL] [Abstract][Full Text] [Related]
58. Carcinogen hemoglobin adducts, urinary mutagenicity, and metabolic phenotype in active and passive cigarette smokers.
Bartsch H; Caporaso N; Coda M; Kadlubar F; Malaveille C; Skipper P; Talaska G; Tannenbaum SR; Vineis P
J Natl Cancer Inst; 1990 Dec; 82(23):1826-31. PubMed ID: 2250298
[TBL] [Abstract][Full Text] [Related]
59. Monoclonal antibodies and rabbit antisera recognizing 4-aminobiphenyl--DNA adducts and application to immunoaffinity chromatography.
Groopman JD; Skipper PL; Donahue PR; Trudel LJ; Wildschutte M; Kadlubar FF; Tannenbaum SR
Carcinogenesis; 1992 Jun; 13(6):917-22. PubMed ID: 1600611
[TBL] [Abstract][Full Text] [Related]
60. DNA adducts in urothelial cells: relationship with biomarkers of exposure to arylamines and polycyclic aromatic hydrocarbons from tobacco smoke.
Vineis P; Talaska G; Malaveille C; Bartsch H; Martone T; Sithisarankul P; Strickland P
Int J Cancer; 1996 Jan; 65(3):314-6. PubMed ID: 8575850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
